New Drug Cocktail Should Boost AbbVie Shares Barron's In fact, AbbVie has eight other drugs in late-stage clinical trials besides its hepatitis C portfolio, including a promising leukemia drug known as ABT-199 and the multiple sclerosis treatment, daclizumab. Still, AbbVie has not been spared the selloff ... |
